Apolipoprotein L1 and Kidney Disease in African Americans

Trends Endocrinol Metab. 2016 Apr;27(4):204-215. doi: 10.1016/j.tem.2016.02.002. Epub 2016 Mar 3.

Abstract

Genetic variants in the Apolipoprotein L1 (APOL1) gene cause high rates of kidney disease in African Americans. These variants, found only in individuals with recent African ancestry, confer enhanced innate immunity against African trypanosomes. Although they are among the most powerful disease-causing common variants discovered to date, we are just beginning to understand how they promote kidney injury. Since APOL1 is present in only a few primate species, much of our current knowledge has come from natural experiments in humans and in vitro studies while awaiting the development of transgenic animal models. Understanding more about the function of ApoL1 and how the high-risk variants behave differently from other ApoL1 molecules is a high priority in kidney disease research.

Keywords: APOL1; African American; apolipoprotein L1; kidney disease.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Africa
  • African Americans / genetics*
  • Animals
  • Apolipoprotein L1
  • Apolipoproteins / blood
  • Apolipoproteins / genetics*
  • Disease Resistance
  • Gene Frequency
  • Genetic Predisposition to Disease
  • Genetic Variation
  • Genotype
  • Humans
  • Kidney Diseases / genetics*
  • Lipoproteins, HDL / blood
  • Lipoproteins, HDL / genetics*
  • Mutation
  • Trypanosomiasis, African / blood
  • Trypanosomiasis, African / immunology

Substances

  • APOL1 protein, human
  • Apolipoprotein L1
  • Apolipoproteins
  • Lipoproteins, HDL